Vertex Pharmaceuticals Azioni (NASDAQ: VRTX)

Ultime notizie per Vertex Pharmaceuticals (NASDAQ:VRTX) Azioni

VERTEX PHARMACEUTICALS INC

Vertex Pharmaceuticals

Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio, and Alyftrek for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex has diversified its portfolio through Casgevy, a gene-editing therapy for beta thalassemia and sickle-cell disease, and Journavx, a non-opioid pain medication approved for the treatment of moderate-to-severe acute pain in adults. Additionally, Vertex is evaluating small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.

Sanofi

News

Short Ideas

Pre-Market Outlook

Markets

Trading Ideas

TSVT

VRTX

L&#39;analisi sui settori più volatili e le strategie per affrontare le incertezze: ecco i trend da seguire per proteggere il tuo portafoglio.

3 titoli che potrebbero non farti dormire sonni tranquilli

Earnings

Long Ideas

VOXX

Analisi pre-mercato, previsioni degli analisti e possibili sorprese: ecco cosa monitorare per investimenti oculati.

McDonald&#39;s, ON Semiconductor e altre 3 azioni da tenere d&#39;occhio oggi

Media

NVDA

POWL

SERV

Un&#39;azienda farmaceutica al centro dell&#39;attenzione: secondo Jim Cramer, è il momento di mantenere le azioni e aspettare notizie positive.

Jim Cramer consiglia di non vendere le azioni di questa azienda farmaceutica

Vertex Pharmaceuticals Incorporated - Common Stock

Vertex Pharmaceuticals Inc

Vertex Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRTX#NASDAQ">VRTX</a>) has outperformed the market over the past 15 years by 6.58% on an annualized basis producing an average annual return of 18.35%. Currently, Vertex Pharmaceuticals has a market capitalization of $114.30 billion. 
Buying $100 In VRTX: If an investor had bought $100 of VRTX stock 15 years ago, it would be worth $1,256.99 today based on a price of $445.10 for VRTX at the time of writing.
<h3>Vertex Pharmaceuticals's Performance Over Last 15 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1748466014_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

If You Invested $100 In This Stock 15 Years Ago, You Would Have This Much Today

This whale alert can help traders discover the next big trading opportunities.
Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner.
Traders will search for circumstances when the market estimation of an option diverges heavily from its normal worth. High amounts of trading activity could push option prices to exaggerated or underestimated levels. 
Below are some instances of options activity happening in the Health Care sector: 
<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>UNH</td>
<td>PUT</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>05/23/25</td>
<td>$300.00</td>
<td>$25.7K</td>
<td>6.4K</td>
<td>7.0K</td>
</tr>
<tr>
<td>MDT</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>06/27/25</td>
<td>$76.00</td>
<td>$244.0K</td>
<td>10</td>
<td>4.0K</td>
</tr>
<tr>
<td>LLY</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>08/15/25</td>
<td>$1000.00</td>
<td>$25.6K</td>
<td>361</td>
<td>274</td>
</tr>
<tr>
<td>SYK</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>06/18/26</td>
<td>$400.00</td>
<td>$52.8K</td>
<td>46</td>
<td>15</td>
</tr>
<tr>
<td>VRTX</td>
<td>PUT</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>06/18/26</td>
<td>$450.00</td>
<td>$30.4K</td>
<td>93</td>
<td>6</td>
</tr>
</tbody>
</table>

<h2>Explanation</h2>
These bullet-by-bullet explanations have been constructed using the accompanying table. 
• For UNH (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNH#NYSE">UNH</a>), we notice a put option trade that happens to be neutral, expiring in 1 day(s) on May 23, 2025. This event was a transfer of 60 contract(s) at a $300.00 strike. The total cost received by the writing party (or parties) was $25.7K, with a price of $429.0 per contract. There were 6422 open contracts at this strike prior to today, and today 7074 contract(s) were bought and sold. 
• For MDT (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MDT#NYSE">MDT</a>), we notice a put option trade that happens to be bullish, expiring in 36 day(s) on June 27, 2025. This event was a transfer of 4000 contract(s) at a $76.00 strike. The total cost received by the writing party (or parties) was $244.0K, with a price of $61.0 per contract. There were 10 open contracts at this strike prior to today, and today 4000 contract(s) were bought and sold. 
• Regarding LLY (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>), we observe a call option sweep with bearish sentiment. It expires in 85 day(s) on August 15, 2025. Parties traded 54 contract(s) at a $1000.00 strike. This particular call needed to be split into 3 different trades to become filled. The total cost received by the writing party (or parties) was $25.6K, with a price of $475.0 per contract. There were 361 open contracts at this strike prior to today, and today 274 contract(s) were bought and sold. 
• For SYK (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SYK#NYSE">SYK</a>), we notice a put option sweep that happens to be bullish, expiring in 392 day(s) on June 18, 2026. This event was a transfer of 12 contract(s) at a $400.00 strike. This particular put needed to be split into 4 different trades to become filled. The total cost received by the writing party (or parties) was $52.8K, with a price of $4400.0 per contract. There were 46 open contracts at this strike prior to today, and today 15 contract(s) were bought and sold. 
• For VRTX (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRTX#NASDAQ">VRTX</a>), we notice a put option trade that happens to be neutral, expiring in 392 day(s) on June 18, 2026. This event was a transfer of 5 contract(s) at a $450.00 strike. The total cost received by the writing party (or parties) was $30.4K, with a price of $6080.0 per contract. There were 93 open contracts at this strike prior to today, and today 6 contract(s) were bought and sold. 
Options Alert Terminology 
 - Call Contracts: The right to buy shares as indicated in the contract. 
 - Put Contracts: The right to sell shares as indicated in the contract. 
 - Expiration Date: When the contract expires. One must act on the contract by this date if one wants to use it. 
 - Premium/Option Price: The price of the contract. 
For more information, visit our <a href="https://pro.benzinga.com/blog/how-to-understand-option-alerts/">Guide to Understanding Options Alerts</a> or read <a href="https://www.benzinga.com/markets/options">more about unusual options activity</a>. 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Options

5 Health Care Stocks Whale Activity In Today's Session

Vertex Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRTX#NASDAQ">VRTX</a>) has outperformed the market over the past 20 years by 10.58% on an annualized basis producing an average annual return of 18.88%. Currently, Vertex Pharmaceuticals has a market capitalization of $114.54 billion. 
Buying $100 In VRTX: If an investor had bought $100 of VRTX stock 20 years ago, it would be worth $3,175.99 today based on a price of $446.03 for VRTX at the time of writing.
<h3>Vertex Pharmaceuticals's Performance Over Last 20 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1747779320_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Here's How Much You Would Have Made Owning Vertex Pharmaceuticals Stock In The Last 20 Years

The Board of Directors of Vertex Pharmaceuticals Incorporated (the "Company") has authorized an additional program to repurchase up to $4.0 billion of the Company's common stock (the "2025 Repurchase Program"). The 2025 Repurchase Program does not have an expiration date and can be discontinued at any time. Under the 2025 Repurchase Program, the Company may repurchase stock from time to time, subject to general business and market conditions and other investment opportunities, on the open market or through privately negotiated transactions, including through Rule 10b5-1 plans.
 &nbsp;
In 2023, the Company's Board of Directors authorized a program to repurchase up to $3.0 billion of the Company's common stock (the "2023 Repurchase Program"). As of May 16, 2025, the Company had approximately $775 million remaining authorization available under the 2023 Repurchase Program. Between the 2025 Repurchase Program and the 2023 Repurchase Program, the Company is authorized to repurchase up to $4.775 billion of the Company's common stock.

Buybacks

Vertex Pharmaceuticals Authorizes $4B Stock Repurchase Program

Analyst Ratings

Live On CNBC, Steve Weiss Announces Sold Vertex Pharmaceuticals

Vertex Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRTX#NASDAQ">VRTX</a>) has outperformed the market over the past 15 years by 6.12% on an annualized basis producing an average annual return of 17.82%. Currently, Vertex Pharmaceuticals has a market capitalization of $112.51 billion. 
Buying $1000 In VRTX: If an investor had bought $1000 of VRTX stock 15 years ago, it would be worth $11,812.35 today based on a price of $438.12 for VRTX at the time of writing.
<h3>Vertex Pharmaceuticals's Performance Over Last 15 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1747152920_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

$1000 Invested In This Stock 15 Years Ago Would Be Worth This Much Today

On CNBC's &#8220;<a href="https://www.cnbc.com/video/2025/05/09/final-trades-vertex-pharma-palantir-wynn-resorts-and-microsoft.html">Halftime Report Final Trades</a>,&#8221; Brenda Vingiello, Chief Investment Officer of Sand Hill Global Advisors, picked Wynn Resorts, Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WYNN#NASDAQ">WYNN</a>) as her final trade.
Wynn Resorts, on May 6, reported quarterly earnings of $1.07 per share which missed the analyst consensus estimate of $1.19 per share. The company reported quarterly sales of $1.7 billion which missed the analyst consensus estimate of $1.74 billion.
Don't forget to check out our <a href="https://www.benzinga.com/premarket/">premarket coverage here </a>
Stephen Weiss, Chief Investment Officer of Short Hills Capital Partners, named Vertex Pharmaceuticals Incorporated (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRTX#NASDAQ">VRTX</a>), <a href="https://in.benzinga.com/general/biotech/25/05/45208824/vertex-pharmaceuticals-stock-falls-on-q1-earnings-revenue-miss-company-raises-low-end-of-fy25-revenue-guidance">saying it will bounce</a>.
On the earnings front, Vertex reported first-quarter adjusted earnings per share of $4.06 on May 5, down from $4.76 a year ago and missing the consensus of $4.32. The cystic fibrosis-focused company reported sales of $2.77 billion, missing the consensus of $2.85 billion.
Kevin Simpson, Capital Wealth Planning CIO, said Palantir Technologies Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLTR#NASDAQ">PLTR</a>) reported impressive earnings, with revenue gaining 39% in the first quarter.
Citigroup analyst Tyler Radke raised the price target on the stock from $110 to $115 on May 8, supporting her view.
Jim Lebenthal of Cerity Partners, named Microsoft Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSFT#NASDAQ">MSFT</a>) as his final trade.
On April 30, Microsoft reported stronger-than-expected financial results for the third quarter and also issued strong revenue guidance.
Price Action:
<ul class="wp-block-list">
<li>Vertex Pharmaceuticals shares fell 1.1% to close at $424.99 on Friday.</li>
<li>Palantir Technologies shares slipped 1.6% to settle at $117.30 during Friday's session.</li>
<li>Wynn Resorts shares rose 1.6% to close at $87.93 on Friday.</li>
<li>Microsoft shares climbed 0.1% to settle at $438.73.</li>
</ul>
Check This Out: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/25/05/45315727/top-3-industrials-stocks-that-may-collapse-in-may">Top 3 Industrials Stocks That May Collapse In May</a></li>
</ul>

MSFT

PLTR

WYNN

Wynn Resorts, Microsoft, Palantir And A Health Care Stock On CNBC's 'Final Trades'

These large-cap stocks were the worst performers in the last week. Are they in your portfolio?
<ol class="wp-block-list">
<li>argenx SE (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARGX#NASDAQ">ARGX</a>) shares tumbled 15.40% after the <a href="https://www.benzinga.com//node/45275849" target="_blank" rel="noreferrer noopener">company reported first-quarter results</a>.</li>
<li>Vertex Pharmaceuticals Incorporated (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRTX#NASDAQ">VRTX</a>) shares dipped 15.20% after it reported lower-than-expected first-quarter 2025 earnings, and analysts <a href="https://www.benzinga.com//node/45236530" target="_blank" rel="noreferrer noopener">revised the price forecasts</a>.</li>
<li>Summit Therapeutics Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMMT#NASDAQ">SMMT</a>) stock fell 14.12%.</li>
<li>MakeMyTrip Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MMYT#NASDAQ">MMYT</a>) shares dived 12.96%.</li>
<li>Regeneron Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/REGN#NASDAQ">REGN</a>) shares fell 12.85%. The U.S. Food and Drug Administration (FDA) announced its intent to expand the use of unannounced inspections at foreign manufacturing facilities that produce foods, essential medicines, and other medical products intended <a href="https://www.benzinga.com//node/45234032" target="_blank" rel="noreferrer noopener">for American consumers and patients</a>.</li>
<li>Rocket Companies, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RKT#NYSE">RKT</a>) shares dived 11.97% after reporting <a href="https://www.benzinga.com//node/45299460" target="_blank" rel="noreferrer noopener">first-quarter results</a>, but issuing a weaker-than-expected Q2 sales outlook.</li>
<li>BioNTech SE (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BNTX#NASDAQ">BNTX</a>) stock was down 11.60% after the <a href="https://www.benzinga.com//node/45205736" target="_blank" rel="noreferrer noopener">company reported quarterly results</a>. Analysts revised the price <a href="https://www.benzinga.com/quote/bntx/analyst-ratings" target="_blank" rel="noreferrer noopener">forecast on the stock</a>.</li>
<li>Affirm Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AFRM#NASDAQ">AFRM</a>) stock declined 11.33% after the company reported third-quarter results and <a href="https://www.benzinga.com//node/45322588" target="_blank" rel="noreferrer noopener">analysts revised the price forecast</a>.</li>
<li>FNF Group of Fidelity National Financial, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FNF#NYSE">FNF</a>) stock declined 10.98% after the company <a href="https://www.benzinga.com//node/45266700" target="_blank" rel="noreferrer noopener">reported first-quarter results</a>.</li>
<li>Eli Lilly and Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>) stock fell 10.81% last week in reaction to an executive order from the Trump administration to boost <a href="https://www.benzinga.com//node/45233995" target="_blank" rel="noreferrer noopener">domestic drug manufacturing</a>.</li>
<li>Aurora Innovation, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AUR#NASDAQ">AUR</a>) stock declined 10.57% after the company reported its<a href="https://www.benzinga.com//node/45300096" target="_blank" rel="noreferrer noopener"> first-quarter financial results</a>. Analysts revised the stock&#8217;s price forecast.</li>
<li>DoorDash, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DASH#NASDAQ">DASH</a>) shares decreased 10.52% after announcing downbeat first-quarter sales, and <a href="https://www.benzinga.com//node/45264549" target="_blank" rel="noreferrer noopener">analysts revised the price forecast</a>.</li>
</ol>
Photo by Jonathan Weiss via Shutterstock

Equities

Large Cap

Movers

AFRM

ARGX

BNTX

DASH

MMYT

REGN

SMMT

Eli Lilly, Affirm And Regeneron Are Among Top 12 Large-Cap Losers Last Week (May 5-May 9): Are The Others In Your Portfolio?

This whale alert can help traders discover the next big trading opportunities.
Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner.
Traders will search for circumstances when the market estimation of an option diverges heavily from its normal worth. High amounts of trading activity could push option prices to exaggerated or underestimated levels. 
Here's the list of options activity happening in today's session: 
<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>MRK</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>05/16/25</td>
<td>$76.00</td>
<td>$46.3K</td>
<td>2.0K</td>
<td>4.3K</td>
</tr>
<tr>
<td>ILMN</td>
<td>CALL</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>09/19/25</td>
<td>$105.00</td>
<td>$32.6K</td>
<td>275</td>
<td>1.3K</td>
</tr>
<tr>
<td>HIMS</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/15/27</td>
<td>$75.00</td>
<td>$45.3K</td>
<td>334</td>
<td>1.1K</td>
</tr>
<tr>
<td>VKTX</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/15/27</td>
<td>$80.00</td>
<td>$32.1K</td>
<td>27</td>
<td>908</td>
</tr>
<tr>
<td>ABBV</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>05/16/25</td>
<td>$192.50</td>
<td>$25.0K</td>
<td>618</td>
<td>726</td>
</tr>
<tr>
<td>GH</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>12/19/25</td>
<td>$22.50</td>
<td>$46.7K</td>
<td>219</td>
<td>73</td>
</tr>
<tr>
<td>UNH</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>06/17/27</td>
<td>$500.00</td>
<td>$43.1K</td>
<td>494</td>
<td>41</td>
</tr>
<tr>
<td>LLY</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>08/15/25</td>
<td>$790.00</td>
<td>$45.0K</td>
<td>160</td>
<td>12</td>
</tr>
<tr>
<td>VRTX</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>10/17/25</td>
<td>$490.00</td>
<td>$32.8K</td>
<td>21</td>
<td>8</td>
</tr>
<tr>
<td>CI</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/15/27</td>
<td>$280.00</td>
<td>$35.8K</td>
<td>1.7K</td>
<td>4</td>
</tr>
</tbody>
</table>

<h2>Explanation</h2>
These bullet-by-bullet explanations have been constructed using the accompanying table. 
• For MRK (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MRK#NYSE">MRK</a>), we notice a put option sweep that happens to be bullish, expiring in 7 day(s) on May 16, 2025. This event was a transfer of 315 contract(s) at a $76.00 strike. This particular put needed to be split into 15 different trades to become filled. The total cost received by the writing party (or parties) was $46.3K, with a price of $147.0 per contract. There were 2065 open contracts at this strike prior to today, and today 4318 contract(s) were bought and sold. 
• Regarding ILMN (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ILMN#NASDAQ">ILMN</a>), we observe a call option sweep with neutral sentiment. It expires in 133 day(s) on September 19, 2025. Parties traded 152 contract(s) at a $105.00 strike. This particular call needed to be split into 4 different trades to become filled. The total cost received by the writing party (or parties) was $32.6K, with a price of $215.0 per contract. There were 275 open contracts at this strike prior to today, and today 1355 contract(s) were bought and sold. 
• Regarding HIMS (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HIMS#NYSE">HIMS</a>), we observe a call option trade with bearish sentiment. It expires in 616 day(s) on January 15, 2027. Parties traded 27 contract(s) at a $75.00 strike. The total cost received by the writing party (or parties) was $45.3K, with a price of $1680.0 per contract. There were 334 open contracts at this strike prior to today, and today 1104 contract(s) were bought and sold. 
• Regarding VKTX (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VKTX#NASDAQ">VKTX</a>), we observe a put option trade with bullish sentiment. It expires in 616 day(s) on January 15, 2027. Parties traded 6 contract(s) at a $80.00 strike. The total cost received by the writing party (or parties) was $32.1K, with a price of $5351.0 per contract. There were 27 open contracts at this strike prior to today, and today 908 contract(s) were bought and sold. 
• Regarding ABBV (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABBV#NYSE">ABBV</a>), we observe a call option sweep with bearish sentiment. It expires in 7 day(s) on May 16, 2025. Parties traded 137 contract(s) at a $192.50 strike. This particular call needed to be split into 40 different trades to become filled. The total cost received by the writing party (or parties) was $25.0K, with a price of $183.0 per contract. There were 618 open contracts at this strike prior to today, and today 726 contract(s) were bought and sold. 
• For GH (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GH#NASDAQ">GH</a>), we notice a call option sweep that happens to be bullish, expiring in 224 day(s) on December 19, 2025. This event was a transfer of 22 contract(s) at a $22.50 strike. This particular call needed to be split into 19 different trades to become filled. The total cost received by the writing party (or parties) was $46.7K, with a price of $2123.0 per contract. There were 219 open contracts at this strike prior to today, and today 73 contract(s) were bought and sold. 
• Regarding UNH (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNH#NYSE">UNH</a>), we observe a call option trade with neutral sentiment. It expires in 769 day(s) on June 17, 2027. Parties traded 10 contract(s) at a $500.00 strike. The total cost received by the writing party (or parties) was $43.1K, with a price of $4315.0 per contract. There were 494 open contracts at this strike prior to today, and today 41 contract(s) were bought and sold. 
• Regarding LLY (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>), we observe a call option trade with bullish sentiment. It expires in 98 day(s) on August 15, 2025. Parties traded 10 contract(s) at a $790.00 strike. The total cost received by the writing party (or parties) was $45.0K, with a price of $4500.0 per contract. There were 160 open contracts at this strike prior to today, and today 12 contract(s) were bought and sold. 
• For VRTX (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRTX#NASDAQ">VRTX</a>), we notice a put option trade that happens to be bearish, expiring in 161 day(s) on October 17, 2025. This event was a transfer of 5 contract(s) at a $490.00 strike. The total cost received by the writing party (or parties) was $32.8K, with a price of $6569.0 per contract. There were 21 open contracts at this strike prior to today, and today 8 contract(s) were bought and sold. 
• For CI (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CI#NYSE">CI</a>), we notice a call option trade that happens to be bullish, expiring in 616 day(s) on January 15, 2027. This event was a transfer of 4 contract(s) at a $280.00 strike. The total cost received by the writing party (or parties) was $35.8K, with a price of $8950.0 per contract. There were 1706 open contracts at this strike prior to today, and today 4 contract(s) were bought and sold. 
Options Alert Terminology 
 - Call Contracts: The right to buy shares as indicated in the contract. 
 - Put Contracts: The right to sell shares as indicated in the contract. 
 - Expiration Date: When the contract expires. One must act on the contract by this date if one wants to use it. 
 - Premium/Option Price: The price of the contract. 
For more information, visit our <a href="https://pro.benzinga.com/blog/how-to-understand-option-alerts/">Guide to Understanding Options Alerts</a> or read <a href="https://www.benzinga.com/markets/options">more about unusual options activity</a>. 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ABBV

Hims & Hers Health, Inc. Class A Common Stock

HIMS

ILMN

VKTX

10 Health Care Stocks With Whale Alerts In Today's Session

CNBC Halftime Report Final Trades: Vertex Pharmaceuticals, Palantir Technologies, Wynn Resorts, Microsoft Corporation

Live On CNBC, Kevin Simpson Announces Sold Vertex Pharmaceuticals

On Monday, Vertex Pharmaceuticals Incorporated (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRTX#NASDAQ">VRTX</a>) reported lower-than-expected first-<a target="_blank" href="https://www.benzinga.com/pressreleases/25/05/b45206073/vertex-reports-first-quarter-2025-financial-results" rel="noreferrer noopener">quarter 2025 earnings</a>.
Vertex reported first-quarter adjusted earnings per share of $4.06, down from $4.76 a year ago, missing <a target="_blank" href="https://www.benzinga.com/calendars/earnings" rel="noreferrer noopener">the consensus of $4.32</a>.
The cystic fibrosis-focused company reported sales of $2.77 billion, missing the consensus of $2.85 billion.
Total revenue&nbsp;increased by 3%, primarily driven by the continued performance of Trikafta/Kaftrio&nbsp;and an early contribution from the&nbsp;U.S.&nbsp;launch of Alyftrek.
<ul>
<li>In the U.S., total revenue increased 9% to $1.66 billion due to continued strong patient demand and higher net realized pricing.</li>
<li>Outside the U.S., total revenue decreased 5% to $1.11 billion, as strong patient demand in established and newer markets was offset by the expected revenue decline in Russia, where Vertex is experiencing a violation of its intellectual property rights. </li>
</ul>
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/25/03/44569612/vertex-discontinues-development-of-type-1-diabetes-candidate-after-disappointing-data" rel="noreferrer noopener">Vertex Discontinues Development Of Type 1 Diabetes Candidate After Disappointing Data</a>
&#8220;Vertex delivered a strong start to 2025 with notable execution across the business as we grow and diversify the revenue base, progress multiple launches and advance the R&amp;D pipeline. We continued to expand our leadership in CF and build global momentum for CASGEVY, and we launched JOURNAVX in moderate-to-severe acute pain,&#8221; said&nbsp;Reshma Kewalramani, CEO and President of&nbsp;Vertex. &#8220;With multiple programs in pivotal development including povetacicept, which continues to make rapid progress in achieving its potential as a pipeline-in-a-product, and additional programs in early and mid-stage development,&nbsp;Vertex&nbsp;is poised to continue to deliver value for years to come.&#8221;
Guidance: Vertex raised the low end of total revenue guidance by&nbsp;$100 million&nbsp;to&nbsp;$11.85&nbsp;billion-$12 billion from $11.75 billion-$12 billion, compared to the consensus of $11.97 billion.
The guidance also includes an immaterial cost impact from tariffs in 2025 based on currently known tariff rates and regulations.
Vertex&nbsp;has temporarily paused the multiple ascending dose portion of the Phase 1/2 study of VX-522, a nebulized CFTR mRNA therapy, to assess a tolerability issue.
William Blair writes, &#8220;While the pause is unfortunate, we believe that the decision to pause the study rather than discontinue it suggests that, beyond the tolerability issue, management is encouraged by the data generated to date given it is open-label.&#8221;
Analyst Myles Minter writes, &#8220;While there was a slight miss on the top line leading to shares trading off 3% in the aftermarket, management raised the lower end of total revenue guidance, suggesting Street estimates may not have fully encompassed the previously disclosed impacts of an unauthorized Trikafta copy in Russia. We would be buyers on weakness here as the CF franchise still represents one of the most stable long-term growth franchises with a competitive moat in the biotech sector.&#8221;
Analyst reactions:
<ul>
<li>Leerink Partners downgrades Vertex from Outperform to Market Perform and lowers the <a href="https://www.benzinga.com/quote/VRTX/analyst-ratings" target="_blank" rel="noreferrer noopener">price target from $550 to $503</a>.</li>
<li>Needham reiterates Vertex Pharmaceuticals from Hold to Hold.</li>
<li>JP Morgan maintains Vertex with an Overweight rating, raising the price target from $512 to $515.</li>
</ul>
Price Action: VRTX stock closed lower by 9.91% at $450.61&nbsp;on Tuesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/05/45234032/fda-expands-surprise-inspections-at-foreign-drug-and-food-facilities-targets-double-standards-in-overseas-manufacturing-oversight" target="_blank" rel="noreferrer noopener">FDA Expands Surprise Inspections At Foreign Drug And Food Facilities, Targets Double Standards In Overseas Manufacturing Oversight</a></li>
</ul>
Photo via Shutterstock

Analyst Color

Biotech

Health Care

Price Target

General

Why Did Vertex Pharmaceuticals Stock Fall On Tuesday?

Wall Street edged lower by midday Tuesday as uncertainty surrounding trade policies lingered, with investors adopting a cautious approach ahead of <a href="https://www.benzinga.com/topic/federal-reserve">Wednesday&#8217;s Federal Reserve meeting.</a>
In a meeting with Canadian Prime Minister Mark Carney, President Donald Trump suggested the U.S. may soon begin renegotiating the USMCA. He noted that China is eager to negotiate due to its struggling economy, driven by a lack of U.S. trade, but emphasized the talks would take place &#8220;at the right time.&#8221;
Trump kept his trade stance unclear, suggesting that while some agreements may be signed, there is no obligation to finalize any, and dismissed repeated questions about the number of deals in progress.
The S&amp;P 500 dipped 30 points, or 0.6%, to 5,610, on track for its second consecutive negative session after nine straight gains. The Nasdaq 100 dropped 0.8%, while the Russell 2000 slipped 1%.
Ten of the 11 S&amp;P 500 sectors were in the red, with utilities as the only sector in the green. The U.S. dollar fell, extending its losses for a third straight session.
Commodities saw a broad rally, with oil prices surging 3.6%, pushing WTI above $59, following <a href="https://www.benzinga.com/economics/macro-economic-events/25/05/45224883/oil-soars-above-59-as-middle-east-airstrikes-jolt-markets">Israeli airstrikes in Yemen</a>. Gold also rallied, climbing 2.4% to above $3,400 per ounce amid heightened geopolitical tensions.
Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) reversed Monday's gains, slipping 0.4% to $94,375.
<h1 class="wp-block-heading">Tuesday&#8217;s Performance In Major U.S. Indices, ETFs</h1>
<figure class="wp-block-table is-style-stripes"> 
<table>
<tbody>
<tr>
<td>Major Indices</td>
<td>Price</td>
<td>1-day % chg</td>
</tr>
<tr>
<td>S&amp;P 500</td>
<td>5,614.65</td>
<td>-0.6%</td>
</tr>
<tr>
<td>Dow Jones</td>
<td>40,905.06</td>
<td>-0.8%</td>
</tr>
<tr>
<td>Nasdaq 100</td>
<td>19,796.10</td>
<td>-0.9%</td>
</tr>
<tr>
<td>Russell 2000</td>
<td>1,983.93</td>
<td colspan="2">-1.0%</td>
</tr>
</tbody>
</table>
<figcaption class="wp-element-caption">Updated by 12:55 p.m. ET</figcaption></figure>
According to&nbsp;<a href="https://www.benzinga.com/pro/?utm_source=BZprocontent&amp;t=be2bearmibe3na1">Benzinga Pro</a>&nbsp;data:
<ul>
<li>The&nbsp;SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>) fell 0.7% to $559.24.</li>
<li>The&nbsp;SPDR Dow Jones Industrial Average&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DIA#NYSE">DIA</a>) eased 0.8% to $409.01.</li>
<li>The tech-heavy&nbsp;Invesco QQQ Trust Series&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>)&nbsp;fell 0.9% to $481.23.</li>
<li>The&nbsp;iShares Russell 2000 ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IWM#NYSE">IWM</a>) tumbled 1.1% to $196.68.</li>
<li>The&nbsp;Utilities&nbsp;Select Sector SPDR Fund (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLU#NYSE">XLU</a>) outperformed, up 1.2%; the&nbsp;Health Care&nbsp;Select Sector SPDR Fund&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLV#NYSE">XLV</a>) lagged, down 2.4%.</li>
</ul>
<h1 class="wp-block-heading">Tuesday&#8217;s Stock Movers</h1>
Stocks reacting to earnings reports included: 
<ul>
<li>Ford Motor Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/F#NYSE">F</a>) up 2.70%</li>
<li>The Clorox Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CLX#NYSE">CLX</a>) down 2.31%</li>
<li>Coterra Energy Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CTRA#NYSE">CTRA</a>) down 9.95%</li>
<li>Vertex Pharmaceuticals Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRTX#NASDAQ">VRTX</a>) down 13.9%</li>
<li>Diamondback Energy Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FANG#NASDAQ">FANG</a>) down 0.53%</li>
<li>Realty Income Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/O#NYSE">O</a>) down 0.68%</li>
<li>The Williams Companies Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WMB#NYSE">WMB</a>) down 5.19%</li>
<li>Celanese Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CE#NYSE">CE</a>) up 9.14%</li>
<li>Fabrinet (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FN#NYSE">FN</a>) down 7.37%</li>
<li>Lattice Semiconductor Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LSCC#NASDAQ">LSCC</a>) down 13.6%</li>
<li>Mattel Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MAT#NASDAQ">MAT</a>) up 3.61%</li>
<li>Palantir Technologies Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PLTR#NYSE">PLTR</a>) down 13.6%</li>
<li>Duke Energy Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DUK#NYSE">DUK</a>) up 2.24%</li>
<li>Constellation Energy Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CEG#NASDAQ">CEG</a>) up 10.94%</li>
<li>TransDigm Group Incorporated (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TDG#NYSE">TDG</a>) down 5.67%</li>
<li>Marriott International, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MAR#NASDAQ">MAR</a>) up 1.26%</li>
<li>Zoetis Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ZTS#NYSE">ZTS</a>) down 3.32%</li>
<li>American Electric Power Company, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AEP#NASDAQ">AEP</a>) up 0.52%</li>
<li>Marathon Petroleum Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MPC#NYSE">MPC</a>) up 0.37%</li>
<li>Fidelity National Information Services, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FIS#NYSE">FIS</a>) down 2.88%</li>
<li>WEC Energy Group, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WEC#NYSE">WEC</a>) up 0.77%</li>
<li>Gartner, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IT#NYSE">IT</a>) up 1.14%</li>
<li>IQVIA Holdings Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IQV#NYSE">IQV</a>) down 1.32%</li>
<li>Archer-Daniels-Midland Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ADM#NYSE">ADM</a>) up 2.02%</li>
<li>Waters Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WAT#NYSE">WAT</a>) down 4.43%</li>
<li>Leidos Holdings, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LDOS#NYSE">LDOS</a>) up 4.11%</li>
<li>Global Payments Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GPN#NYSE">GPN</a>) down 1.43%</li>
<li>GlobalFoundries Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GFS#NASDAQ">GFS</a>) down 3.57%</li>
<li>Expeditors International of Washington, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EXPD#NYSE">EXPD</a>) down 3.67%</li>
<li>Ball Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BALL#NYSE">BALL</a>) up 0.55%</li>
<li>Jacobs Solutions Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/J#NYSE">J</a>) down 5.56%</li>
</ul>
Stocks slated to report earnings after the close include: Assurant Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AIZ#NYSE">AIZ</a>), Arista Networks Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ANET#NYSE">ANET</a>), Gen Digital Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GEN#NASDAQ">GEN</a>), Advanced Micro Devices Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMD#NASDAQ">AMD</a>), International Flavors &amp; Fragrances Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IFF#NYSE">IFF</a>), Electronic Arts Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EA#NASDAQ">EA</a>), Mosaic Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MOS#NYSE">MOS</a>), Corpay Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CPAY#NYSE">CPAY</a>), Wynn Resorts Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WYNN#NASDAQ">WYNN</a>), Jack Henry &amp; Associates Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JKHY#NASDAQ">JKHY</a>), Devon Energy Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DVN#NYSE">DVN</a>), Super Micro Computer Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMCI#NASDAQ">SMCI</a>), Coty Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/COTY#NYSE">COTY</a>) and Rivian Automotive Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RIVN#NASDAQ">RIVN</a>).
Read now: 
<ul>
<li><a href="https://www.benzinga.com/news/large-cap/25/05/45205780/sp-500-stocks-that-defy-sell-in-may-myth-5-companies-with-strong-historical-gains">S&amp;P 500 Stocks That Defy &#8216;Sell In May&#8217; Myth: 5 Companies With Strong Historical Gains</a></li>
</ul>
Photo: Gumbariya via Shutterstock

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

Government

Macro Economic Events

Mid Cap

Regulations

Sector ETFs

Broad U.S. Equity ETFs

Commodities

Small Cap

Global

Econ #s

Economics

ETFs

$BTC

ANET

BALL

COTY

CPAY

CTRA

SPDR Dow Jones Industrial Average ETF Trust

EXPD

FANG

JKHY

LDOS

LSCC

RIVN

SMCI

Select Sector SPDR-Consumer Discretionary

Stocks Fall On Trade Concerns, Oil And Gold Rally: What's Driving Markets Tuesday?

RBC Capital analyst Brian Abrahams maintains Vertex Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRTX#NASDAQ">VRTX</a>) with a Sector Perform and raises the price target from $420 to $423.

RBC Capital Maintains Sector Perform on Vertex Pharmaceuticals, Raises Price Target to $423

Scotiabank analyst Greg Harrison maintains Vertex Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRTX#NASDAQ">VRTX</a>) with a Sector Perform and lowers the price target from $450 to $442.

Scotiabank Maintains Sector Perform on Vertex Pharmaceuticals, Lowers Price Target to $442

Morgan Stanley analyst Matthew Harrison maintains Vertex Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRTX#NASDAQ">VRTX</a>) with a Equal-Weight and raises the price target from $462 to $464.

Morgan Stanley Maintains Equal-Weight on Vertex Pharmaceuticals, Raises Price Target to $464

JP Morgan analyst Jessica Fye maintains Vertex Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRTX#NASDAQ">VRTX</a>) with a Overweight and raises the price target from $512 to $515.

JP Morgan Maintains Overweight on Vertex Pharmaceuticals, Raises Price Target to $515

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul>
<li>Needham cut ON Semiconductor Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ON#NASDAQ">ON</a>) price target from $57 to $50. Needham analyst Quinn Bolton maintained a Buy rating. ON Semiconductor shares closed at $38.41 on Monday. See how other analysts <a href="https://www.benzinga.com/quote/ON/analyst-ratings">view this stock</a>.</li>
<li>Compass Point slashed the price target for MARA Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MARA#NASDAQ">MARA</a>) from $25 to $9.5. Compass Point analyst Joe Flynn downgraded the stock from Neutral to Sell. MARA Holdings shares closed at $13.09 on Monday. <a href="https://www.benzinga.com/quote/MARA/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Leerink Partners cut Vertex Pharmaceuticals Incorporated (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRTX#NASDAQ">VRTX</a>) price target from $550 to $503. Leerink Partners analyst David Risinger downgraded the stock from Outperform to Market Perform. Vertex Pharmaceuticals shares closed at $500.19 on Monday. See how other analysts view <a href="https://www.benzinga.com/quote/VRTX/analyst-ratings">this stock</a>.</li>
<li>HC Wainwright &amp; Co. raised the price target for Solaris Resources Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SLSR#NYSE">SLSR</a>) from $10 to $11. HC Wainwright &amp; Co. analyst Heiko Ihle maintained a Buy rating. Solaris Resources shares closed at $4.33 on Monday. <a href="https://www.benzinga.com/quote/SLSR/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Telsey Advisory Group slashed the price target for Ethan Allen Interiors Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ETD#NYSE">ETD</a>) from $32 to $30. Telsey Advisory Group analyst Cristina Fernandez maintained a Market Perform rating. Ethan Allen Interiors shares closed at $29.13 on Monday. See how other analysts <a href="https://www.benzinga.com/quote/ETD/analyst-ratings">view this stock</a>.</li>
<li>Rosenblatt raised Fabrinet (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FN#NYSE">FN</a>) price target from $230 to $250. Rosenblatt analyst Mike Genovese maintained a Buy rating. Fabrinet shares settled at $220.90 on Monday. <a href="https://www.benzinga.com/quote/FN/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Telsey Advisory Group cut NIKE, Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NKE#NYSE">NKE</a>) price target from $80 to $70. Telsey Advisory Group analyst Cristina Fernandez maintained a Market Perform rating. Nike shares closed at $57.35 on Monday. <a href="https://www.benzinga.com/quote/NKE/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Canaccord Genuity cut Castle Biosciences, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CSTL#NASDAQ">CSTL</a>) price target from $42 to $37. Canaccord Genuity analyst Kyle Mikson maintained a Buy rating. Castle Biosciences shares closed at $18.75 on Monday.  <a href="https://www.benzinga.com/quote/cstl/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>JP Morgan cut the price target for Twist Bioscience Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TWST#NASDAQ">TWST</a>) from $40 to $33. JP Morgan analyst Rachel Vatnsdal maintained an Underweight rating. Twist Bioscience shares settled at $35.93 on Monday. <a href="https://www.benzinga.com/quote/MSFT/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>JP Morgan raised Quest Diagnostics Incorporated (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DGX#NYSE">DGX</a>) price target from $180 to $190. JP Morgan analyst Lisa Gill maintained a Neutral rating. Quest Diagnostics shares closed at $177.57 on Monday. <a href="https://www.benzinga.com/quote/DGX/analyst-ratings">See how other analysts view this stock</a>.</li>
</ul>
Considering buying NKE stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="581" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/06080300/image-53-1024x581.png" alt="" class="wp-image-903102" style="width:591px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/06080300/image-53-1024x581.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/06080300/image-53-300x170.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/06080300/image-53-768x436.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/06080300/image-53.png 1116w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read This Next: 
<ul>
<li><a href="https://www.benzinga.com/markets/25/05/45192607/jim-cramer-applied-materials-is-an-excellent-company-but-likes-this-tech-stock-more">Jim Cramer Says Applied Materials Is An &#8216;Excellent&#8217; Company, But Likes This Tech Stock More</a> </li>
</ul>
Photo via Shutterstock

CSTL

MARA

SLSR

TWST

Nike To $70? Here Are 10 Top Analyst Forecasts For Tuesday

Cantor Fitzgerald analyst Carter Gould reiterates Vertex Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRTX#NASDAQ">VRTX</a>) with a Overweight and maintains $535 price target.

Reiteration

Cantor Fitzgerald Reiterates Overweight on Vertex Pharmaceuticals, Maintains $535 Price Target

Needham analyst Joseph Stringer reiterates Vertex Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRTX#NASDAQ">VRTX</a>) from Hold to Hold.

Needham Reiterates Hold on Vertex Pharmaceuticalsto Hold

Press Releases

Vertex Announces CASGEVY® Reimbursement Agreement for the Treatment of Sickle Cell Disease in England

Vertex Reports Fourth Quarter and Full Year 2024 Financial Results

AM Best Assigns Credit Ratings to Torreyana Insurance Company, Inc.

Vertex to Participate in Upcoming March Investor Conferences

Coeptis Inc. (COEP) Expands Cancer Immunotherapy Portfolio with Exclusive GEAR Cell Therapy License

Vertex Announces Program Updates for Type 1 Diabetes Portfolio

Vertex to Announce First Quarter 2025 Financial Results on May 5th

Vertex Researcher, Paul Negulescu Ph.D., Receives the 2025 Canada Gairdner International Award for Pioneering Research and Discovery of Medicines for Cystic Fibrosis

Vertex Reports First Quarter 2025 Financial Results

Vertex to Participate in Upcoming Investor Conferences

ALNY

COEP

RPRX

AbbVie

Alnylam Pharmaceuticals, Inc. - Common Stock

Alnylam Pharmaceuticals

Amgen

argenx

Ascendis Pharma A/S - American Depositary Shares

Ascendis Pharma

Biogen

BioMarin Pharmaceutical Inc. - Common Stock

Biomarin Pharmaceutical

BioNTech

Blueprint Medicines Corporation - Common Stock

Blueprint Medicines

Exact Sciences Corporation - Common Stock

Exact Sciences

Exelixis

Gilead Sciences

Genmab

Halozyme Therapeutics, Inc. - Common Stock

Halozyme Therapeutics

Incyte

Insmed

Moderna

Neurocrine Biosciences, Inc. - Common Stock

Neurocrine Biosciences

Natera

BeOne Medicines Ltd. - American Depositary Shares

BeOne Medicines

Regeneron Pharmaceuticals, Inc. - Common Stock

Regeneron Pharmaceuticals

Roivant Sciences

Revolution Medicines, Inc. - Common Stock

Revolution Medicines

Summit Therapeutics

United Therapeutics Corporation - Common Stock

Comments

Vertex Pharmaceuticals

Notizie

Ultime notizie per Vertex Pharmaceuticals (NASDAQ:VRTX) Azioni

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO